Calls for papers
-
The ALS Association, which supports research on amyotrophic lateral sclerosis, has awarded a grant to Tiziana Life Sciences to support a clinical trial of intranasal foralumab in 20 patients with ALS at Massachusetts General Hospital,… Read more . . .
-
Nocion Therapeutics has announced the initiation of the Phase 2b ASPIRE clinical trial of its NOC-110 inhaled dry powder taplucainium (formerly NTX-1175) in patients with chronic cough. Earlier this year, the company said that it… Read more . . .
-
NurExone Biologic announced that the EMA has granted orphan medicinal product designation to NurExone’s ExoPTEN intranasal exosome therapy, which the company is developing for the treatment of spinal cord injury. In 2023, the FDA granted orphan drug… Read more . . .
-
AlveoGene’s AVG-002 inhaled gene therapy gets rare pediatric disease designation for SP-B deficiency
UK-based start-up AlveoGene announced that its AVG-002 nebulized gene therapy for neonatal surfactant protein B (SP-B) deficiency has received a rare pediatric disease designation from the FDA. The company says that it will advance AVG-002… Read more . . .
-
Pulmatrix has announced a planned merger with biopharma Cullgen, which is developing oral protein degraders for the treatment of various indications. In anticipation of the merger, Pulmatrix says that it will divest inhalation assets, including… Read more . . .
-
Danish pharma company ALK says that it is paying ARS Pharmaceuticals $145 million up front and up to $320 million in potential milestone payments plus royalties for the rights to neffy intranasal adrenaline (epinephrine) everywhere except the… Read more . . .
-
Aptar Pharma will commercialize and promote Cambridge Healthcare Innovations’ Quattrii blister-based dry powder inhaler platform, the companies said. According to the announcement, the platform is tunable and can be used with carrier or API-only formulations.… Read more . . .
-
Inhalation CDMO Bespak recently announced that it will close its site in Research Triangle Park, NC, USA by the end of the first quarter of 2025. Bespak spun out from Recipharm earlier this year with… Read more . . .
-
CRO OzUK has announced the availability of a new GLP pilot plant designed for pilot and feasibility studies of both solution and suspension MDIs filled with low global warming potential (LGWP) propellants. OzUK announced plans… Read more . . .
-
Tiziana Life Sciences announced that a preclinical study of its intranasal foralumab in combination with semaglutide (Ozempic / Wegovy) demonstrated synergistic effects in a mouse model of obesity, improving liver function and reducing inflammation more… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland